Identifying RNA Biomarkers and Molecular Pathways Involved in Multiple Subtypes of Uveitis.
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
07
06
2020
revised:
06
01
2021
accepted:
06
01
2021
pubmed:
28
1
2021
medline:
11
9
2021
entrez:
27
1
2021
Statut:
ppublish
Résumé
Uveitis is a heterogeneous collection of diseases. We tested the hypothesis that despite the diversity of uveitides, there could be common mechanisms shared by multiple subtypes, and that evidence of these common mechanisms may be detected as gene expression profiles in whole blood. Cohort study. Ninety subjects with uveitis including axial spondyloarthritis (n = 17), sarcoidosis (n = 13), inflammatory bowel disease (n = 12), tubulointerstitial nephritis with uveitis (n = 10), or idiopathic uveitis (n = 38) as well as 18 healthy controls were enrolled, predominantly at Oregon Health & Science University. RNA-Seq data generated from peripheral, whole blood identified 19,859 unique transcripts. We analyzed gene expression pathways via Kyoto Encyclopedia of Genes and Genomes and Gene Ontology (GO). We validated our list of upregulated genes by comparison to a previously published study on peripheral blood gene expression among 50 subjects with diverse forms of uveitis. Both the Kyoto Encyclopedia of Genes and Genomes and GO analysis identified multiple shared pathways or GO terms with a P value of <.0001. Almost all pathways related to the immune response and/or response to an infection. A total of 119 individual transcripts were upregulated by at least 1.5-fold and false discovery rate <.05, and 61 were downregulated by similar criteria. Comparing mRNA from our study with a false discovery rate <.05 and the prior report, we identified 10 common gene transcripts: ICAM1, IL15RA, IL15, IRF1, IL10RB, GSK3A, TYK2, MEF2A, MEF2B, and MEF2D. Many forms of uveitis share overlapping mechanisms. These data support the concept that a single therapeutic approach could benefit diverse forms of this disease.
Identifiants
pubmed: 33503442
pii: S0002-9394(21)00027-1
doi: 10.1016/j.ajo.2021.01.007
pmc: PMC8286715
mid: NIHMS1668466
pii:
doi:
Substances chimiques
Eye Proteins
0
Genetic Markers
0
RNA, Messenger
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-234Subventions
Organisme : NIAMS NIH HHS
ID : P30 AR073752
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States
Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY026572
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
J Dermatolog Treat. 2018 Sep;29(6):569-578
pubmed: 29532693
Clin Rheumatol. 2020 Sep;39(9):2573-2581
pubmed: 32206975
Arthritis Rheumatol. 2016 Feb;68(2):282-98
pubmed: 26401991
Scand J Rheumatol. 2018 Jul;47(4):276-281
pubmed: 29458278
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2563-6
pubmed: 11581199
Sci Rep. 2020 Apr 14;10(1):6271
pubmed: 32286338
Rheumatology (Oxford). 2020 Oct 1;59(10):2816-2828
pubmed: 32047926
Oncotarget. 2017 Dec 4;8(67):112152-112165
pubmed: 29340119
Invest Ophthalmol Vis Sci. 2011 Sep 01;52(9):6919-24
pubmed: 21498606
J Immunol. 2019 Mar 15;202(6):1724-1734
pubmed: 30718299
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Lancet. 2016 Sep 17;388(10050):1183-92
pubmed: 27542302
Expert Rev Clin Immunol. 2020 Mar;16(3):335-341
pubmed: 32067517
Int Ophthalmol. 1990 Oct;14(5-6):303-8
pubmed: 2249907
N Engl J Med. 2016 Sep 8;375(10):932-43
pubmed: 27602665
Nat Biotechnol. 2014 Sep;32(9):896-902
pubmed: 25150836
Ann Rheum Dis. 2020 Jun;79(6):713-723
pubmed: 32220834
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3741-3749
pubmed: 28738418
Arch Ophthalmol. 1984 Apr;102(4):572-5
pubmed: 6608345
Genes Cells. 2015 May;20(5):408-26
pubmed: 25757744
Clin Drug Investig. 2010;30(9):613-24
pubmed: 20626209
Mod Rheumatol. 2014 May;24(3):481-6
pubmed: 24645721
Scand J Immunol. 2013 Jan;77(1):39-53
pubmed: 23126655
Genome Biol. 2010;11(2):R14
pubmed: 20132535
Expert Opin Ther Pat. 2019 Feb;29(2):137-149
pubmed: 30621465
Am J Ophthalmol. 2021 Feb;222:15-23
pubmed: 32941857
J Immunol. 2008 Oct 1;181(7):5147-57
pubmed: 18802119
J Cell Biochem. 2017 Dec;118(12):4275-4284
pubmed: 28422321
Ann Rheum Dis. 2017 Mar;76(3):543-546
pubmed: 27474764
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
Genes Dev. 2016 Oct 15;30(20):2297-2309
pubmed: 27898394
J Immunol. 1995 Oct 15;155(8):4090-4
pubmed: 7561121
Hum Immunol. 2007 Sep;68(9):770-8
pubmed: 17869652
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Gut. 2012 Dec;61(12):1693-700
pubmed: 22595313
J Immunol. 2000 Mar 1;164(5):2807-14
pubmed: 10679124
PLoS One. 2012;7(9):e45801
pubmed: 23029250
Front Immunol. 2018 Mar 13;9:504
pubmed: 29662488
Immunity. 2019 Apr 16;50(4):871-891
pubmed: 30995504
Neurology. 2012 Feb 14;78(7):458-67; discussion 465
pubmed: 22302546
Eye (Lond). 2012 Jun;26(6):862-5
pubmed: 22402699